Hepcidin and Hfe in iron overload in β-thalassemia

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 221-225

  Gardenghi, Sara ^a   Ramos, Pedro ^a   Follenzi, Antonia ^b   Rao, Niva ^a   Rachmilewitz, Eliezer A ^c   Giardina, Patricia J ^a   Grady, Robert W ^a   Rivella, Stefano ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c WOLFSON MEDICAL CENTER   (Israel)

Author keywords

hepcidin; Hfe; iron overload; lentiviral vectors; thalassemia

Indexed keywords

FERROPORTIN; FLUROTHYL; HAMP25; HEPCIDIN; IRON; PEPTIDE; UNCLASSIFIED DRUG;

ANEMIA; BETA THALASSEMIA; COLORIMETRY; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; ERYTHROPOIESIS; INTESTINE CELL; IRON ABSORPTION; IRON BLOOD LEVEL; IRON METABOLISM; IRON OVERLOAD; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; RETICULOCYTE COUNT; TH3 CELL;

EID: 77955906936     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05595.x     Document Type: Conference Paper

References (29)

1. Krause, A. et al. 2000. LEAP-1, a novel highly disulfidebonded human peptide, exhibits antimicrobial activity. FEBS Lett . 480: 147-150.
2. Park, C.H. et al. 2001. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 276: 7806-7810.
3. Nemeth, E. et al. 2004.Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093.
4. Pak, M. et al. 2006. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 108: 3730-3735.
5. Nicolas, G. et al. 2002. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110: 1037-1044.
6. Pigeon, C. et al. 2001. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 276: 7811-7819.
7. Nemeth, E. et al. 2003. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101: 2461-2463.
8. Nemeth, E. et al. 2004. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113: 1271-1276.
9. Wrighting, D.M. & N.C. Andrews. 2006. Interleukin-6 induces hepcidin expression through STAT3. Blood 108: 3204-3209.
10. Bannerman, R.M. et al. 1967. Thalassemia intermedia, with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyrinuria. Am. J. Med. 42: 476-486.
11. Giardina, P.J. & R.W. Grady. 2001. Chelation therapy in beta-thalassemia: an optimistic update. Semin. Hematol. 38: 360-366.
12. Pippard, M.J. et al. 1979. Iron absorption and loading in beta-thalassaemia intermedia. Lancet 2: 819-821.
13. Nicolas, G. et al. 2001. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc. Natl. Acad. Sci. USA 98: 8780-8785.
14. Nemeth, E. & T. Ganz. 2009. The role of hepcidin in iron metabolism. Acta Haematol. 122: 78-86.
15. Adamsky, K. et al. 2004. Decreased hepcidin mRNA expression in thalassemic mice. Br. J. Haematol. 124: 123-124.
16. Gardenghi, S. et al. 2007. Ineffective erythropoiesis in {beta}-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and upregulation of ferroportin. Blood 109: 5027-5035.
17. Weizer-Stern, O. et al. 2006. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and betathalassemia major mouse models. Am. J. Hematol. 81: 479-483.
18. DeFranceschi, L. et al. 2006. Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. Haematologica 91: 1336-1342.
19. Rivera, S. et al. 2005. Synthetic hepcidin causes rapid dosedependent hypoferremia and is concentrated in ferroportincontaining organs. Blood 106: 2196-2199.
20. Gardenghi, S. et al. 2008. Increased hepcidin expression in Mice affected by-thalassemia reduces iron overload with no effect on Anemia. Blood 112: 53.
21. Follenzi, A. et al. 2002. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene. Ther. 13: 243-260.
22. Costa, R.H. & D.R. Grayson. 1991. Site-directed mutagenesis of hepatocyte nuclear factor (HNF) binding sites in the mouse transthyretin (TTR) promoter reveal synergistic interactions with its enhancer region. Nucleic Acids Res. 19: 4139-4145.
23. Vigna, E. et al. 2005. Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector. Mol. Ther. 11: 763-775.
24. Follenzi, A. et al. 2000. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25: 217-222.
25. Zufferey, R. et al. 1999. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73: 2886-2892.
26. Zufferey, R. et al. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72: 9873-9880.
27. Zufferey, R. et al. 1997.Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15: 871-875.
28. Naldini, L. et al. 1996. in vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector [see comments]. Science 272: 263-267.
29. Naldini, L. et al. 1996. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93: 11382-11388.